Cyltezo-Phase III -in Psoriasis

Biosimilar Cyltezo ® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasisData show that Cyltezo © (adalimumab- adbm) and Humira®* have similar efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis1At week 16, the study met the primary endpoint, demonstrating clinical equivalence to Humira ®1Data will be presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018)
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news